Moreover, in the single‐arm phase‐II NeoATP trial, the pre‐defined locoregional pCR (ypT0/is ypN0) was achieved in 39 (73.6%) of 53 patients with locally advanced HER2‐positive breast cancer who received four cycles of pyrotinib and trastuzumab with weekly paclitaxel–cisplatin as neoadjuvant treatment.26 This evidence concerns the gene ERBB2 and breast carcinoma.